# Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

> **NCT03983239** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 32 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Fedratinib
- **DRUG:** Rifampin
- **DRUG:** Efavirenz

## Key facts

- **NCT ID:** NCT03983239
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-21
- **Primary completion:** 2019-11-02
- **Final completion:** 2019-11-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-08-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03983239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03983239, "Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03983239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*